Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Shanghai Liuwei Dihuang Pill presbycusis study

Also known as: Liuwei Dihuang Pill, Liu Wei Di Huang Pill, RLDP, NCT05125081

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Completed

Target Gene

—

Route / Mode

Oral pill

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

China

Population

older-adult, age-related, sensorineural, tinnitus, traditional-chinese-medicine

Trial IDs

Mechanism

Completed randomized Phase 2 study of oral Liuwei Dihuang Pill versus placebo for adults with presbycusis and Shen/Kidney-yin deficiency, with speech-recognition and audiologic endpoints.

Indications

Hearing Loss Sensorineural Hearing Loss Age-Related Hearing Loss Tinnitus

Notes

Corrected from a marketed-product-in-China row to the completed Shanghai institution-led RLDP Phase 2 study. The registry says the study product was donated by a pharmaceutical company, but no commercial hearing-loss sponsor/program owner was verified.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT05125081

Open

Key Events

2022-01-25

RLDP Liuwei Dihuang presbycusis trial started

2024-12-25

Registry lists study completion date

2026-01-07